Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cilengitide may stop the growth of brain metastases by blocking blood flow to the
tumor. Radiation therapy uses high energy X-rays to kill tumor cells. Giving cilengitide
together with radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of cilengitide when
given together with whole-brain radiation therapy in treating patients with brain metastases
from lung cancer.